Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
STEP 1: This trial had 1,961 obese or overweight adults who didn't suffer from type 2 diabetes received either the 2.4 mg dosage or placebo to assess their weight loss
All regulatory agencies are awaiting Phase 3 data Phase 2 results: Up to 24.2% weight loss at 48 weeks, the highest efficacy data for any GLP-1 class medication Commercial launch timeline: FDA submission expected 2026-2027, with 6-12 month review period International rollout: EMA (Europe) and TGA (Australia) typically follow FDA approval within 6-18 months Is retatrutide available
If you have been on 15mg for at least 12 weeks and have lost less than 5% of your starting body weight despite good dietary compliance and regular exercise, that suggests non-response rather than a simple plateau
Type 2 E10.40 is the equivalent code for Type 1 diabetes mellitus with diabetic neuropathy, unspecified
